Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Pharmacyclics (PCYC) -- Ignore unavailable to you. Want to Upgrade?

To: Biomaven who wrote (436)	5/10/1999 11:17:00 PM
From: Doug Meetmer	Read Replies (1) \| Respond to of 717

$50 would not be extreme if Gd-Tex approval was imminent, but we still are awaiting trial data, and then an NDA, and then the infamous FDA advisory meeting. Lots of room for both ups and downs in stock price prior to approval. I suspect that Antrin will be a failure. I didn't get the sense that those preliminary phase I results were that overwhelming. What you need in a cardiovascular drug is the ability to say that it is good enough to supplant existing technology. That will be a major hurdle, particularly with Coronary artery angioplasty, where there is A LOT of money at stake. Considering how many cardiologists are trained to do angiplasty, how many companies make balloons and stents, etc.. I think the resistance would be huge.